CSL Limited

CSL Limited is a global biotechnology company that develops and delivers innovative biotherapies and influenza vaccines to protect public health and help people with life-threatening medical conditions live full lives. Founded in 1916 as the Commonwealth Serum Laboratories in Melbourne, Australia, CSL has grown into a leading global biotech company with a dynamic portfolio of life-saving products in immunology, hematology, vaccines, and transplant therapy.

History

CSL was established in 1916 to service the health needs of a nation isolated by war, focusing initially on the production of vaccines and antitoxins. Over the decades, CSL has expanded its focus to include research, development, manufacture, and marketing of a broad range of products to treat and prevent serious human medical conditions.

Operations

Today, CSL operates on a global scale with major facilities in Australia, the United States, Germany, Switzerland, and the UK, among others. The company operates through two main divisions: CSL Behring and Seqirus. CSL Behring is focused on immunoglobulins, plasma-derived therapies, and recombinant products. Seqirus, established following CSL's acquisition of the Novartis influenza vaccine business in 2015, is the world's second-largest influenza vaccine provider.

Products and Research

CSL's product range includes treatments for conditions such as hemophilia, von Willebrand disease, primary immunodeficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company is also a leading provider of influenza vaccines and antivenoms. CSL invests heavily in research and development, focusing on new and improved therapies that can address unmet medical needs.

Corporate Responsibility

CSL is committed to corporate responsibility, with a focus on patient safety, ethical practices in research and development, environmental sustainability, and supporting the communities in which it operates. The company's efforts in these areas are detailed in its annual Corporate Responsibility Report.

Challenges and Controversies

Like many companies in the pharmaceutical and biotechnology sectors, CSL has faced challenges and controversies, including issues related to product safety, pricing, and access to treatments. The company works with regulatory bodies around the world to ensure that its products meet stringent safety and efficacy standards.

Future Directions

CSL continues to invest in the future, with a strong pipeline of potential new therapies and ongoing expansion into new markets. The company's focus on innovation, patient care, and global health needs positions it to remain a leader in the biotechnology industry for years to come.